These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17472831)

  • 21. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
    Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
    Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
    Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
    Collins CD; Schwemm AK
    Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No mercy for MRSA: treatment alternatives to vancomycin and linezolid.
    Wegner DL
    MLO Med Lab Obs; 2005 Jan; 37(1):26-9. PubMed ID: 15743145
    [No Abstract]   [Full Text] [Related]  

  • 28. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
    Chavanet P
    Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linezolid better than vancomycin in treating drug-resistant pneumonia.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Apr; 15(7):1, 6-7. PubMed ID: 15101393
    [No Abstract]   [Full Text] [Related]  

  • 33. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Linezolid versus vancomycin in the treatment of pneumonia caused by Gram-positive cocci: meta-analysis of randomised controlled trials].
    Lin ZQ; Huang YL; Huang P; Chen Q
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec; 33(12):900-6. PubMed ID: 21211409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
    Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
    Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment options for nosocomial pneumonia due to MRSA.
    Niederman MS
    J Infect; 2009 Sep; 59 Suppl 1():S25-31. PubMed ID: 19766886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
    Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
    Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
    Nathwani D
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
    Vinken A; Li Z; Balan D; Rittenhouse B; Wilike R; Nathwani D
    J Hosp Infect; 2001 Dec; 49 Suppl A():S13-24. PubMed ID: 11926436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.